<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">Thrombus</z:e> formation is a key step in the pathophysiology of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> and results from the activation of the coagulation cascade </plain></SENT>
<SENT sid="1" pm="."><plain>Thrombin plays a central role in this coagulation system and contributes to <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> stability via activation of thrombin-activatable fibrinolysis inhibitor (TAFIa) </plain></SENT>
<SENT sid="2" pm="."><plain>TAFIa counteracts endogenous fibrinolysis at different stages and elevated TAFI levels are a risk factor for thrombotic events including <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Although substantial in vitro data on the influence of TAFI on the coagulation-fibrinolysis-system exist, investigations on the consequences of TAFI inhibition in animal models of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> are still lacking </plain></SENT>
<SENT sid="4" pm="."><plain>In the present study we analyzed <z:hpo ids='HP_0001297'>stroke</z:hpo> development and post <z:hpo ids='HP_0001297'>stroke</z:hpo> functional outcome in TAFI-/- mice </plain></SENT>
<SENT sid="5" pm="."><plain>METHODOLOGY/PRINCIPAL FINDINGS: TAFI-/- mice and <z:mp ids='MP_0002169'>wild-type</z:mp> controls were subjected to 60 min transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (tMCAO) using the intraluminal filament method </plain></SENT>
<SENT sid="6" pm="."><plain>After 24 hours, functional outcome scores were assessed and <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes were measured from 2,3,5-Triphenyltetrazoliumchloride (TTC)-stained brain slices </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="1" ids="51686">Hematoxylin</z:chebi> and eosin (H&amp;E) staining was used to estimate the extent of neuronal cell damage </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">Thrombus</z:e> formation within the infarcted brain areas was analyzed by immunoblot </plain></SENT>
<SENT sid="9" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> volumes and functional outcomes did not significantly differ between TAFI-/- mice and controls (p&gt;0.05) </plain></SENT>
<SENT sid="10" pm="."><plain>Histology revealed extensive ischemic neuronal damage regularly including the cortex and the basal ganglia in both groups </plain></SENT>
<SENT sid="11" pm="."><plain>TAFI deficiency also had no influence on intracerebral fibrin(ogen) formation after tMCAO </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: Our study shows that TAFI does not play a major role for <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation and <z:mp ids='MP_0002229'>neuronal degeneration</z:mp> after ischemic brain challenge </plain></SENT>
</text></document>